ZR001 Chemogenetics Gene Therapy Study in Patients With Parkinson's Disease

This study aims to evaluate the safety, tolerability, and preliminary efficacy of ZR001, a novel chemogenetic gene therapy product, in patients with moderately advanced Parkinson's disease (PD). ZR001 is administered via stereotactic injection into the bilateral substantia nigra, followed by postoperative ultra-low-dose clozapine to activate the transduced direct pathway, with the goal of improving motor symptoms of Parkinson's disease.

NCT Number	NCT07718659
Lead Sponsor	Qianfoshan Hospital Collaborators: Shenzhen Loongen Biotechnology Co., Ltd.
Conditions	Parkinson's Disease (PD), Parkinsonian Disorders
Enrollment	8 participants
Start Date	2026-12-01
Primary Completion	2029-12-01 (estimated)
Study Completion	2030-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-22